Serious vaccine risks accepted by FDA
Serious Adverse Eventshttps://www.fda.gov/media/186738/download?attachment
MNEXSPIKE group
Serious adverse events were reported by 2.7% of participants (n=156)
Comparator vaccine
Serious adverse events were reported by and 2.6% of participants (n=151)
(median follow-up of 8.8 months).
https://cardiovascular-research-and-innovation.reseaprojournals.com/archive_files/Myocarditis%20after%20SARS-CoV-2%20infection%20and%20COVID-19%20vaccination%20Epidemiology,%20outcomes,%20and%20new%20perspectives.pdf
https://investors.modernatx.com/news/news-details/2025/Moderna-Receives-U-S--FDA-Approval-for-COVID-19-Vaccine-mNEXSPIKE/default.aspx
https://www.fda.gov/vaccines-blood-biologics/mnexspike
Targeted approach against the JN.1 variant
Participants received either mRNA-1283 or mRNA-1273.
mRNA-1283 showed a 9.3% higher relative vaccine efficacy (rVE) compared to mRNA-1273 in individuals aged 12 years and older,
a 13.5% higher rVE in adults aged 65 and older.
https://clinicaltrials.gov/study/NCT05815498
https://ctv.veeva.com/study/a-study-of-mrna-1283222-injection-compared-with-mrna-1273222-injection-in-participants-12-years-o
https://ctv.veeva.com
CONTRAINDICATIONS
Do not administer MNEXSPIKE to individuals with a known history of severe allergic reaction
Myocarditis and Pericarditis,
increased risks of myocarditis and pericarditis,
risk has been highest in males 12 years through 24 years of age.
Onset of symptoms typically in the first week following vaccination
Although some individuals with myocarditis and/or pericarditis following administration of mRNA COVID-19 vaccines have required intensive care support,
available data suggest that individuals typically have resolution of symptoms within a few days with conservative management.
In hospitalized patients who had been diagnosed with COVID-19 vaccine-associated myocarditis,
Most of these patients had received a two-dose primary series of an mRNA COVID-19 vaccine prior to their diagnosis.
In this study,
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(24)00388-2/fulltext
at a median follow-up of approximately 5 months post-vaccination, persistence of abnormal cardiac magnetic resonance imaging (CMR) findings that are a marker for myocardial injury was common.
The clinical and prognostic significance of these CMR findings is not known
Information is not yet available about potential long-term sequelae of myocarditis or pericarditis following administration of mRNA COVID-19 vaccines.
5.3 Syncope
Syncope (fainting) may occur in association with administration of injectable vaccines.
5.4 Altered Immunocompetence
Immunocompromised persons, including individuals receiving immunosuppressive therapy, may have a diminished immune response to MNEXSPIKE
5.5 Limitations of Vaccine Effectiveness
MNEXSPIKE may not protect all vaccine recipients.
6 ADVERSE REACTIONS
Most commonly (≥10%) reported adverse reactions following administration of MNEXSPIKE: Receive SMS online on sms24.me
TubeReader video aggregator is a website that collects and organizes online videos from the YouTube source. Video aggregation is done for different purposes, and TubeReader take different approaches to achieve their purpose.
Our try to collect videos of high quality or interest for visitors to view; the collection may be made by editors or may be based on community votes.
Another method is to base the collection on those videos most viewed, either at the aggregator site or at various popular video hosting sites.
TubeReader site exists to allow users to collect their own sets of videos, for personal use as well as for browsing and viewing by others; TubeReader can develop online communities around video sharing.
Our site allow users to create a personalized video playlist, for personal use as well as for browsing and viewing by others.
@YouTubeReaderBot allows you to subscribe to Youtube channels.
By using @YouTubeReaderBot Bot you agree with YouTube Terms of Service.
Use the @YouTubeReaderBot telegram bot to be the first to be notified when new videos are released on your favorite channels.
Look for new videos or channels and share them with your friends.
You can start using our bot from this video, subscribe now to Serious vaccine risks accepted by FDA
What is YouTube?
YouTube is a free video sharing website that makes it easy to watch online videos. You can even create and upload your own videos to share with others. Originally created in 2005, YouTube is now one of the most popular sites on the Web, with visitors watching around 6 billion hours of video every month.
